Explore every episode of the podcast Labcorp Perspectives: Oncology
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Why Comprehensive Testing Matters—Ken Schlosser’s Lung Cancer Story | 01 Aug 2025 | 00:23:16 | |
A Real Story of Hope, Testing, and Targeted Care. In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019. Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped guide a treatment path that has kept him thriving for more than six years. They also discuss the role of patient education and advocacy in expanding access to precision testing, as well as why understanding your biomarker status can make a significant difference in care outcomes. This episode offers an inspiring look at how data-driven decisions can transform lives and why testing is crucial from the outset. Listen to the full conversation now. Follow Us
Presented by Labcorp Oncology | |||
| Rethinking How We Track and Treat Cancer | 14 Jul 2025 | 00:19:28 | |
Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer. In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting. They explore Labcorp’s HER2 expression study in breast cancer, which found significant changes in HER2 status over time, and what that means for retesting and clinical decisions. Michelle and Rebecca also discuss new data on HER3-targeting antibody-drug conjugates, including the potential for treating both breast and lung cancers, and advances in ctDNA testing across tumor types. From molecular profiling to liquid biopsy, this episode provides a wide-ranging look at how new tools and emerging biomarkers are shaping the future of personalized oncology care. Listen to the full conversation now. Follow Us
Presented by Labcorp Oncology | |||
| Tumor-Agnostic Therapies and the Future of HER2 in Oncology | 09 Jun 2025 | 00:20:35 | |
Tumor biology is rewriting the rules of cancer treatment. They unpack what these FDA approvals actually mean in clinical practice, why HER2 is becoming relevant far beyond breast and gastric cancer, and how biomarkers like ERBB2 amplification and HER2 protein expression are shaping decisions across tumor types. Dr. Ko shares her insights from the DESTINY-PanTumor02 trial, discusses why tissue stewardship is more important than ever, and breaks down what oncologists need to know about interpreting HER2 data across IHC, FISH, and NGS. Whether you’re navigating biomarker testing workflows or just trying to keep up with precision oncology’s fast pace, this episode offers timely context and clear clinical takeaways. Tune in now. Follow Us
Presented by Labcorp Oncology | |||
| Why Genetic Testing Should Be Standard in Prostate Cancer | 19 May 2025 | 00:19:00 | |
Genetic testing is no longer optional — it’s essential. Welcome to the first episode of Labcorp Perspectives: Oncology, where host Dr. Rebecca Previs sits down with Sarah Young, a genetic counselor and Clinical Program Manager for Oncology at Labcorp, to talk about the growing importance of genetic testing in prostate cancer care. Sarah shares insights from the recent American Urological Association (AUA) conference, where she helped lead the first plenary session focused on genetic testing in urologic oncology. Together, they discuss the latest research supporting universal germline testing, the clinical relevance of both germline and somatic testing, and how this information can directly influence treatment decisions, including eligibility for targeted therapies like PARP inhibitors. They also explore barriers to adoption, including provider education gaps, complex guidelines, and limited access to genetics professionals, and offer practical solutions like mainstream testing, digital education tools, and Labcorp’s post-test counseling support. Hear how broader testing strategies are reshaping care pathways, improving outcomes, and helping to close gaps for high-risk and historically underserved patient populations. Tune in now. Follow Us
Presented by Labcorp Oncology | |||